Ceftiofur

From Wikipedia, the free encyclopedia

Ceftiofur
Systematic (IUPAC) name
(6R,7R)-7-[ [(2Z)-2-(2-Amino-1,3-thiazol-4-yl)-2-methoxyiminoacetyl]amino]-3-(furan-2-carbonylsulfanylmethyl)-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
Identifiers
CAS number 80370-57-6
ATC code  ?
PubChem  ?
Chemical data
Formula C19H17N5O7S3 
Mol. mass 523.56 g/mol
Pharmacokinetic data
Bioavailability  ?
Metabolism  ?
Half life  ?
Excretion  ?
Therapeutic considerations
Pregnancy cat.

?

Legal status
Routes  ?

Ceftiofur is an antibiotic of the cephalosporin type (third generation), licensed for use in veterinary medicine. It was first described in 1987.[1] It is marketed by pharmaceutical company Pfizer as Excede.[2]

It is resistant to the antibiotic resistance enzyme beta-lactamase, and has activity against Gram-positive and Gram-negative bacteria. E. coli strains resistant to ceftiofur have been reported.[3]

[edit] References

  1. ^ Yancey RJ, Kinney ML, Roberts BJ, Goodenough KR, Hamel JC, Ford CW (1987). "Ceftiofur sodium, a broad-spectrum cephalosporin: evaluation in vitro and in vivo in mice". Am. J. Vet. Res. 48 (7): 1050–3. PMID 3631686. 
  2. ^ Pfizer Animal ealth Dairy Information on Products and Solutions. Retrieved on 2007-11-20.
  3. ^ Donaldson SC, Straley BA, Hegde NV, Sawant AA, DebRoy C, Jayarao BM (2006). "Molecular epidemiology of ceftiofur-resistant Escherichia coli isolates from dairy calves". Appl. Environ. Microbiol. 72 (6): 3940–8. doi:10.1128/AEM.02770-05. PMID 16751500. 

[edit] External links